Uso de plasma de convaleciente en el tratamiento de paciente con neumonía por COVID-19. Reporte de caso
- Avila Rueda, Jhon Alexander 1
- Rabinovich, Oscar
- Young, Pablo
- Trimarchi, Hernán
- Montes, Agustín
- Jordán, Rossana
- Martínez, Jorge
- Finn, Bárbara
- Murias, Gastón
- Ceresetto, José
- Duboscq, Cristina
- Ernst, Glenda
- Acosta, José
- Cimillo, Flavia
- Alvarado, Gilda
- Sernaque, Ceciclia
- Flegler, Nicolas
- Oliveros, Karla
- Rivarola, Sofía
- Stemmelin, Germán
-
1
Hospital Británico de Buenos Aires
info
ISSN: 0329-0379, 2250-8309
Year of publication: 2020
Volume: 24
Issue: 2
Pages: 73-79
Type: Article
More publications in: Revista Hematología
Abstract
Sars-Cov-2, known as COVID-19, is a virus belonging to coronavirus family, whose characteristicis the development of respiratory diseases, mainly pneumonia, with a high risk of progression to acute respiratory distress syndrome, which in turn is related to high morbidity and mortality rates that vary from case to case. Although a specific management scheme is not available, the use of convalescent plasma has been proposed as a therapeutic alternative, so studies are currently being carried out to evaluate its efficacy, although there are preliminary reports of published studies with encouraging results with low risk and possible benefits of this therapy. We present our case experience regarding the use of convalescent plasma in a 24 years old patient diagnosed with COVID-19 pneumonia at our institution.
Bibliographic References
- Ackermann M, Verleden SE, Kuehnel M. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020; 383: 120-8.
- Beigel JH, Tomashek KM, Dodd LE. Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med. 2020; NEJMoa2007764.
- Cao B, Wang Y, Wen D. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382: 1787-99.
- Doremalen N, Munster V. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARSCoV-1. N Engl J Med. 2020; 382:1564-7.
- Duan K, Liu B, Li C. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 2020; 117(17): 9490-6.
- Gárgano C, Piaz A. Fiebre hemorrágica Argentina. Conflictos y desafíos para la ciencia en el ámbito rural. Asclepio. 2017; 69: 178-84.
- Joyner M, Wright RS, Fairweather D. Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients. J Clin Invest. 2020.
- Hoffmann M, Kleine-Weber H, Schroederet S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181: 271-80.
- Horby P, Lim HS, Embersonet JR. RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020;10.1056/NEJMoa2021436.
- Huang C, Wang Y, Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
- Lauer SA, Grantz KH, Bi Q. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020 Ann Intern Med. 2020; 172(9): 577-82.
- Li l, Zhang W, Hu Y. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19. A Randomized Clinical Trial. JAMA. 2020. e2010044.
- Mair-Jenkins J, Saavedra-Campos M, Baillie JK.The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis. J Infect Dis. 2015; 211(1): 80-90.
- Woo PC, Huang Y, Lau SK, Yuen KY. Coronavirus genomics and bioinformatics analysis. Viruses. 2010; 2(8): 1804-20.
- Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. J Infect. 2020; 80(6): 607-13.